From the American Academy of Ophthalmology

Investigators evaluated blood samples from 8 patients with type 1 ROP before and 8 weeks after bevacizumab treatment. All patients received 0.625 mg of bevacizumab. The anti-VEGF entered systemic circulation 1 day after treatment and remained detectable for 2 months. No changes were identified in the serum levels of other growth factors. The authors recommend that bevacizumab be used with caution in the treatment of ROP. JAMA Ophthalmology, April 2015